Both Vyvanse and tricyclic antidepressants can have side effects that affect your heart, such as a fast or irregular heartbeat
New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity
Sterile water for injection (SWI) has no preservative, so the reconstituted solution is only stable for 24 hours when refrigerated
Retatrutide is an investigational 39-amino-acid, fatty-acid-acylated triple agonist engineered to engage the GIP, GLP-1, and glucagon receptors from a single peptide backbone
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
Proglucagon processing in porcine and human pancreas
